Nexthera Capital’s Clearside Biomedical CLSD Stock Holding History

Nexthera Capital’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-12,067	Closed	-$1.11M	–	30
2018 Q3	$1.11M	Buy	+12,067	New	+$1.43M	0.21%	44
2017 Q2	–	Sell	-8,051	Closed	-$959K	–	44
2017 Q1	$959K	Hold	8,051	–	–	0.49%	27
2016 Q4	$1.08M	Buy	+8,051	New	+$2.02M	0.63%	31

Other funds holding CLSD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nexthera Capital's CLSD Position: Q4 2018 in Review

Nexthera Capital sold out of Clearside Biomedical (CLSD) in Q4 2018, closing a stake of 12,067 shares — an estimated $1.11M sold.

Nexthera Capital first reported a position in CLSD in Q4 2016 and held it in 3 quarters. The position peaked at $1.11M in Q3 2018. 69 funds tracked by Wall St. Rank hold CLSD as of Q4 2018.

Nexthera Capital reported no remaining Clearside Biomedical position as of Q4 2018 after selling out during the quarter.
Nexthera Capital sold 12,067 Clearside Biomedical shares in Q4 2018, an estimated $1.11M.
Nexthera Capital first reported a position in Clearside Biomedical in Q4 2016 and held it in 3 quarters.
Nexthera Capital's Clearside Biomedical position peaked at $1.11M in Q3 2018.
69 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2018.

Based on Nexthera Capital's 13F filing for Q4 2018, filed 14 Feb 2019.